Omeros Corporation - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Omeros Corporation - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Omeros Corporation - Product Pipeline Review - 2015', provides an overview of the Omeros Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Omeros Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Omeros Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Omeros Corporation's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Omeros Corporation's pipeline products

Reasons to Buy

- Evaluate Omeros Corporation's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Omeros Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Omeros Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Omeros Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Omeros Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Omeros Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Omeros Corporation Snapshot 6
Omeros Corporation Overview 6
Key Information 6
Key Facts 6
Omeros Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Omeros Corporation - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Omeros Corporation - Pipeline Products Glance 16
Omeros Corporation - Clinical Stage Pipeline Products 16
Omeros Corporation - Early Stage Pipeline Products 17
Omeros Corporation - Drug Profiles 21
OMS-405 21
OMS-721 22
Monoclonal Antibodies to Antagonize FN14 for Oncology 24
Monoclonal Antibodies to Antagonize FZD10 for Oncology 26
Monoclonal Antibodies to Antagonize Tie2 for Oncology 28
Monoclonal Antibodies to Antagonize VEGFR2 for Oncology 30
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications 32
Monoclonal Antibodies to Inhibit TROP2 for Oncology 34
OMS-527 36
OMS-616 37
OMS-906 38
Small Molecule to Agonize GPR52 for Schizophrenia 39
Small Molecule to Agonize PTH-1R for Osteoporosis 40
Small Molecule to Antagonize GPR101 for Appetite Disorders 41
Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders 42
Small Molecule to Antagonize GPR139 for Motor Control 43
Small Molecule to Antagonize GPR15 for Rheumatoid Arthritis and HIV-Mediated Enteropathy 44
Small Molecule to Antagonize GPR161 for Metastatic Epithelial Cancers, Congenital Cataracts and Birth Defects of the Brain and Spinal Cord 45
Small Molecule to Antagonize GPR17 for Central Nervous System Disorders 46
Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia 47
Small Molecule to Antagonize GPR182 for Pancreatic Cancer 48
Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer 49
Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia 50
Small Molecule to Antagonize GPR27 for Obesity and Schizophrenia 51
Small Molecule to Antagonize GPR31 for Anxiety Disorders 52
Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes 53
Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia 54
Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia 55
Small Molecule to Antagonize GPR87 for Cancer 56
Small Molecule to Antagonize NMUR2 for Pain 57
Small Molecule to Antagonize OPN4 for Circadian Rhythm Irregularities and Sleep Disorders 58
Small Molecule to Antagonize P2Y8 for Acute Lymphoblastic Leukemia 59
Small Molecule to Inhibit CCRL2 for Rheumatoid Arthritis and Immune Disorders 60
Small Molecule to Target GPR132 for Atherosclerosis 61
Small Molecule to Target GPR141 for Respiratory and Immune Disorders 62
Small Molecule to Target GPR150 for Ovarian Cancer 63
Small Molecule to Target GPR151 for CNS Diseases 64
Small Molecule to Target GPR153 for Schizophrenia 65
Small Molecule to Target GPR162 for Neuropsychiatric Disorders 66
Small Molecule to Target GPR171 for Eating and Hematological Disorders 67
Small Molecule to Target GPR174 for Melanoma and Grave's Disease 68
Small Molecule to Target GPR176 for Atherosclerosis 69
Small Molecule to Target GPR183 for Humoral Immunity 70
Small Molecule to Target GPR21 for Obesity and Diabetes 71
Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis 72
Small Molecule to Target GPR25 for Arterial Stiffness 73
Small Molecule to Target GPR37 for Parkinson's Disease 74
Small Molecule to Target GPR37L1 for Hypertension and Cardiac Hypertrophy 75
Small Molecule to Target GPR50 for CNS and Metabolic Disorders 76
Small Molecule to Target GPR63 for Autism 77
Small Molecule to Target GPR65 for Oncology and Inflammatory Disorders 78
Small Molecule to Target GPR80 for Hepatocellular Carcinoma 79
Small Molecule to Target GPR82 for Appetite Disorders and Body Weight 80
Small Molecule to Target GPR83 for CNS and Immunological Disorders 81
Small Molecule to Target LGR4 for Cancer and Osteoporosis 82
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma 83
Small Molecule to Target LGR6 for Wound Repair and Formation of New Hair Follicles 84
Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer 85
Small Molecule to Target MRGE for Pain 86
Small Molecule to Target MRGF for Pain 87
Small Molecule to Target OGR1 for Oncology, Bone Diseases, Asthma and Osteoporosis 88
Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis 89
Omeros Corporation - Pipeline Analysis 90
Omeros Corporation - Pipeline Products by Target 90
Omeros Corporation - Pipeline Products by Route of Administration 92
Omeros Corporation - Pipeline Products by Molecule Type 93
Omeros Corporation - Pipeline Products by Mechanism of Action 94
Omeros Corporation - Recent Pipeline Updates 96
Omeros Corporation - Dormant Projects 101
Omeros Corporation - Discontinued Pipeline Products 102
Discontinued Pipeline Product Profiles 102
Omeros Corporation - Locations And Subsidiaries 103
Head Office 103
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 104
Disclaimer 105

List of Tables

Omeros Corporation, Key Information 10
Omeros Corporation, Key Facts 10
Omeros Corporation - Pipeline by Indication, 2015 12
Omeros Corporation - Pipeline by Stage of Development, 2015 18
Omeros Corporation - Monotherapy Products in Pipeline, 2015 19
Omeros Corporation - Phase II, 2015 20
Omeros Corporation - Preclinical, 2015 21
Omeros Corporation - Discovery, 2015 24
Omeros Corporation - Pipeline by Target, 2015 94
Omeros Corporation - Pipeline by Route of Administration, 2015 96
Omeros Corporation - Pipeline by Molecule Type, 2015 97
Omeros Corporation - Pipeline Products by Mechanism of Action, 2015 98
Omeros Corporation - Recent Pipeline Updates, 2015 100
Omeros Corporation - Dormant Developmental Projects,2015 105
Omeros Corporation - Discontinued Pipeline Products, 2015 106